Market data not licensed for redistribution.

Celltrion

068270 · KOSPI · Manufacture of Basic Pharmaceutical Products

– Previous close pending (official data.go.kr feed not active yet) Live price ↗

Source: Financial Services Commission stock price data (data.go.kr), updated once a day.

Daily price, 1 year

Key statistics

Market cap (KRW bn)–

PER–

PBR–

ROE %8.8

Debt ratio % (liabilities / equity)31

Revenue TTM (KRW bn)4,897.8

Op. profit TTM (KRW bn)1,550.2

Dividend yield %–

Basis: market cap at …; equity = total equity (consolidated if available) at 2026.06.30; net income = trailing 12 months to 2026.06.30 (consolidated). PER is not shown when TTM net income is negative.

Upcoming risk events

Next 90 days for this company, plus macro events tagged with this ticker or its sector. Not a recommendation.

No scheduled risk events found (last checked 2026-10-30 19:40 KST).

See it in the full calendar →

Annual results (KRW bn)

	2021	2022	2023	2024	2025
Revenue	1,911.6	2,284.0	2,176.4	3,557.3	4,162.5
Operating profit	756.9	647.2	651.5	492.0	1,168.5
Net income	595.8	542.6	539.7	418.9	1,031.5

Quarterly results (KRW bn, 3 months)

	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	841.9	961.5	1,029.0	1,330.2	1,145.0	1,393.7
Operating profit	149.4	242.5	301.4	475.2	321.9	451.8
Net income	108.3	63.3	331.9	527.9	349.8	371.3

Largest shareholder

As of the 2025 annual report: (주)셀트리온홀딩스 and related parties hold 31.15% of common shares.

Recent disclosures

Date	Filing	Summary
2026-10-30	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서		DART original
2026-10-30	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서		DART original
2026-10-30	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서		DART original
2026-10-30	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서		DART original
2026-10-30	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서		DART original
2026-10-27	Preliminary earnings [기재정정]연결재무제표기준영업(잠정)실적(공정공시)	Celltrion: Preliminary earnings	DART original
2026-10-27	Insider / major-holder ownership report 주식등의대량보유상황보고서(일반)		DART original
2026-10-26	Share buyback decision 주요사항보고서(자기주식취득결정)		DART original
2026-10-22	Other material event (investment-relevant) 투자판단관련주요경영사항 (반감기 연장 기술이 적용된 장기 지속형 항APRIL 항체 Licensein 계약 체결)	Celltrion: Other material event (investment-relevant)	DART original
2026-10-20	Governance / misc. (routine) 자기주식취득결과보고서		DART original
2026-10-14	Clinical trial / regulatory approval 투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 한국 임상 3상 시험계획 승인)		DART original
2026-10-12	Preliminary earnings 연결재무제표기준영업(잠정)실적(공정공시)		DART original

Past material filings and price reaction (market-adjusted)

Date	Filing type	On the news (vs. market)	Next day (vs. market)	20 days (vs. market)
2026-10-14	Clinical trial / regulatory approval	+5.0%	+4.0%	–
2026-10-12	Preliminary earnings	+2.1%	+2.1%	–
2026-09-29	Share buyback decision	+0.6%	-0.2%	–
2026-09-23	Clinical trial / regulatory approval	-1.5%	+3.2%	–
2026-09-21	Clinical trial / regulatory approval	-0.5%	-1.7%	–
2026-09-16	Share cancellation	+1.0%	-2.5%	–
2026-09-07	Clinical trial / regulatory approval	-2.9%	-2.6%	-1.3%
2026-08-31	Share buyback decision	-1.4%	-0.7%	-6.2%
2026-08-25	Clarification of rumor / inquiry	+1.1%	-0.1%	-11.0%
2026-08-24	Clinical trial / regulatory approval	+1.7%	+2.3%	-8.0%

For information only, not investment advice. Data may be delayed or inaccurate. Full disclaimer → Data: OpenDART (FSS), stock prices: official previous-day close from the Financial Services Commission (data.go.kr) and FinanceData/marcap history, index data via FinanceDataReader, FX: ECB reference rates, crypto data from Upbit, Bithumb and Binance public APIs.
Market data not licensed for redistribution.
© Crypvu · Crypto market view